■VMENr 
APPENDIX D TO APPENDIX C 
DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE 
PUBLIC HEALTH SERVICE 
NATIONAL INSTITUTES OF HEALTH 
BETHESDA. MARYLAND 20014 
August 26, 1976 
MEMORANDUM 
To; NIH Grantee Institutions and Contractors 
From; Director 
Office of Recombinant nsiA Activities 
Subject; Implementation of NIH Guidelines for Research 
Involving Recombinant ENA Molecules 
NOTICE ; This Memorandum Requires Your Immediate Attention and Possible 
Necessary Action . 
I . Background 
On May 5, the Director, NIH, established the Office of 
Recombinant DNA Activities (ORDA) in the National Institute 
of General Medical Sciences to coordinate the administration 
of NIH policies and procedures pertaining to the utilization 
of recombinant ENA technology in research. 
On June 23, the NIH issued Guidelines for Research Involving 
Recombinant ENA Molecules. You have already received or will 
receive in the near future a copy of these guidelines. These 
guidelines will govern the conduct of NIH supported research 
on recombinant DNA molecules, and they establish carefully 
controlled conditions for the conduct of experiments involving 
the production of such molecules and their insertion into 
organisms such as bacteria. 
These guidelines replace the recommendations contained in the 
1975 Summary Statement of the Asilomar Conference on Recombinant 
DNA Molecules . 
Within the next few months, detailed procedures for the sub- 
mission, review and monitoring of projects involving recombinant 
DNA technology will be published in the NIH Guide for Grants and 
Contracts . 
The purpose of this communication is to inform you of interim 
procedures which must be undertaken immediately if NIH supported 
recombinant ENA research is currently being conducted or will 
be conducted in the future at your institution. 
Appendix C — 20 
